A novel liposomal influenza vaccine (INFLUSOME-VAC) containing hemagglutinin-neuraminidase and IL-2 or GM-CSF induces protective anti-neuraminidase antibodies cross-reacting with a wide spectrum of influenza A viral strains

被引:48
作者
Babai, I
Barenholz, Y
Zakay-Rones, Z
Greenbaum, E
Samira, S
Hayon, I
Rochman, M
Kedar, E
机构
[1] Hebrew Univ Jerusalem, Hadassah Med Sch, Lautenberg Ctr Gen & Tumor Immunol, IL-91120 Jerusalem, Israel
[2] Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, Lab Membrane & Liposome Res, IL-91120 Jerusalem, Israel
[3] Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Virol, IL-91120 Jerusalem, Israel
基金
以色列科学基金会;
关键词
influenza vaccine; liposomes; cytokines; neuraminidase;
D O I
10.1016/S0264-410X(01)00326-7
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A liposomal influenza vaccine (INFLUSOME-VAC) was developed with the objective of overcoming the major drawbacks of the currently used influenza vaccines: their relatively low efficacy in certain high-risk groups (the elderly, infants, the immunosuppressed) and the need for annual immunization. INFLUSOME-VAC consists of liposomes containing the viral surface proteins hemagglutinin (HA) and neuraminidase (NA) derived from various influenza strains and IL-2 or GM-CSF, as an adjuvant. Vaccination of mice showed that, whereas conventional vaccines induced a low- and short-term response against HA and very low or no anti-NA response, INFLUSOME-VAC produced high titers of both anti-HA and anti-NA antibodies (Abs) in young and old mice that persisted for at least 6 months. Moreover, the anti-NA Abs efficiently cross-reacted with several N2 viral subtypes spanning 20 years. and such vaccines afforded partial protection against heterosubtypic viral infection. (C) 2001 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:505 / 515
页数:11
相关论文
共 46 条
  • [1] Alving C.R, 1997, NEW GENERATION VACCI, P207
  • [2] Askonas B, 1982, BASIC APPLIED INFLUE
  • [3] AYMARDHENRY M, 1973, B WORLD HEALTH ORGAN, V48, P199
  • [4] A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. I. Vaccine characterization and efficacy studies in mice
    Babai, I
    Samira, S
    Barenholz, Y
    Zakay-Rones, Z
    Kedar, E
    [J]. VACCINE, 1999, 17 (9-10) : 1223 - 1238
  • [5] A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. II. Induction of TH1 and TH2 responses in mice
    Babai, I
    Samira, S
    Barenholz, Y
    Zakay-Rones, Z
    Kedar, E
    [J]. VACCINE, 1999, 17 (9-10) : 1239 - 1250
  • [6] THE SUBCLASS IGG RESPONSES OF MICE TO INFLUENZA SURFACE-PROTEINS FORMULATED INTO LIPOSOMES
    BENAHMEIDA, ETS
    JENNINGS, R
    TAN, L
    GREGORIADIS, G
    POTTER, CW
    [J]. ANTIVIRAL RESEARCH, 1993, 21 (03) : 217 - 231
  • [7] Immune response to influenza vaccination in a large healthy elderly population
    Bernstein, E
    Kaye, D
    Abrutyn, E
    Gross, P
    Dorfman, M
    Murasko, DM
    [J]. VACCINE, 1999, 17 (01) : 82 - 94
  • [8] EVALUATION OF A NEURAMINIDASE-SPECIFIC INFLUENZA-A VIRUS-VACCINE IN CHILDREN - ANTIBODY-RESPONSES AND EFFECTS ON 2 SUCCESSIVE OUTBREAKS OF NATURAL INFECTION
    BEUTNER, KR
    CHOW, T
    RUBI, E
    STRUSSENBERG, J
    CLEMENT, J
    OGRA, PL
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1979, 140 (06) : 844 - 850
  • [9] ENHANCEMENT OF THE PROTECTIVE EFFECT OF INACTIVATED INFLUENZA-VIRUS VACCINE BY CYTOKINES
    CAO, M
    SASAKI, O
    YAMADA, A
    IMANISHI, J
    [J]. VACCINE, 1992, 10 (04) : 238 - 242
  • [10] Comparative analysis of six European influenza vaccines
    Chaloupka, I
    Schuler, A
    Marschall, M
    MeierEwert, H
    [J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1996, 15 (02) : 121 - 127